VG Life Sciences, Inc. Announces Management Changes
SANTA BARBARA, Calif., July 18, 2013 /PRNewswire/ -- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces alterations in its corporate management and management structure.
Interim CEO & President
John Tynan has been named Interim CEO & President of VG Life Sciences, inc, effective immediately. Mr. Tynan started TynanGroup, Inc. in 1991 and grew it to successful company as a leader in real estate development services across the country, overseeing more than $4 billion of construction. TynanGroup was on INC Magazine's list of the fasting growing companies and today includes a host of sister companies including MedBridge Development Company, LLC and Anchor Point IT Solutions. Prior to starting TynanGroup, he was Vice President for Hyatt Development Corporation where he oversaw $1.5 Billion project expenditures and over 9,000 people. Mr. Tynan has a BS in Civil Engineering from the University of Illinois and a MBA in finance from DePaul University. "My focus is on achieving specific goals to increase shareholders' value and support our exceptional research team," said Tynan. Haig Keledjian will stay on as Chairman of the Board and VP of Intellectual Property and Product Development.
For more information on the goals and direction of the company as well as the new management structure of VG Life Sciences, please see the July 18th, 2013 investor letter, which can be downloaded from the company site and viewed here.
About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious diseases, and autoimmune disorders. VGLS controls over 50 US and international patents and pending patents protecting its exclusive biotech platform technologies. For more information, visit www.vglifesciences.com.
Alexandria Sumner, Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
SOURCE VG Life Sciences, Inc.
More by this Source
VG Life Sciences, Inc. Announces the Initiation of IND-Enabling Animal Safety Studies
Nov 04, 2013, 06:00 ET
US Patent Office Issues Patent for VG Life Sciences' Peptide for HIV Treatment
Oct 31, 2013, 06:00 ET
VG Life Sciences, Inc. Update on Phase I Cancer Study
Dec 13, 2013, 06:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.